Two distinct chimeric potexviruses share antigenic cross-presentation properties of MHC class I epitopes

Laïla Aïcha Hanafi, Marilène Bolduc, Marie Ève Laliberté Gagné, Florent Dufour, Yves Langelier, Mohammed Rachid Boulassel, Jean Pierre Routy, Denis Leclerc, Réjean Lapointe

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Chimeric VLPs made of papaya mosaic virus (PapMV) trigger a CTL response through antigenic presentation of epitopes on MHC class I. Here, a chimeric VLP composed of malva mosaic virus (MaMV) was shown to share similar properties. We demonstrated the capacity of both VLPs to enter human APCs. The chimeric constructions were cross-presented in CD40-activated B lymphocytes leading to in vitro expansion of antigen-specific T lymphocytes. We showed that high concentrations of chimeric MaMV induced cell death, suggesting that some modifications can trigger collateral effects in vitro. Results suggest that potexvirus VLPs are an attractive vaccine platform for inducing a CTL response.

Original languageEnglish
Pages (from-to)5617-5626
Number of pages10
JournalVaccine
Volume28
Issue number34
DOIs
Publication statusPublished - Aug 2010

Fingerprint

Malva mosaic virus
Potexvirus
Cross-Priming
Mosaic Viruses
Malva
epitopes
Papaya mosaic virus
Epitopes
B-lymphocytes
Carica
cell death
T-lymphocytes
vaccines
antigens
B-Lymphocytes
Cell Death
Vaccines
T-Lymphocytes
Antigens

Keywords

  • Cross-presentation
  • Potexvirus
  • Virus-like particles

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Hanafi, L. A., Bolduc, M., Gagné, M. È. L., Dufour, F., Langelier, Y., Boulassel, M. R., ... Lapointe, R. (2010). Two distinct chimeric potexviruses share antigenic cross-presentation properties of MHC class I epitopes. Vaccine, 28(34), 5617-5626. https://doi.org/10.1016/j.vaccine.2010.06.024

Two distinct chimeric potexviruses share antigenic cross-presentation properties of MHC class I epitopes. / Hanafi, Laïla Aïcha; Bolduc, Marilène; Gagné, Marie Ève Laliberté; Dufour, Florent; Langelier, Yves; Boulassel, Mohammed Rachid; Routy, Jean Pierre; Leclerc, Denis; Lapointe, Réjean.

In: Vaccine, Vol. 28, No. 34, 08.2010, p. 5617-5626.

Research output: Contribution to journalArticle

Hanafi, LA, Bolduc, M, Gagné, MÈL, Dufour, F, Langelier, Y, Boulassel, MR, Routy, JP, Leclerc, D & Lapointe, R 2010, 'Two distinct chimeric potexviruses share antigenic cross-presentation properties of MHC class I epitopes', Vaccine, vol. 28, no. 34, pp. 5617-5626. https://doi.org/10.1016/j.vaccine.2010.06.024
Hanafi, Laïla Aïcha ; Bolduc, Marilène ; Gagné, Marie Ève Laliberté ; Dufour, Florent ; Langelier, Yves ; Boulassel, Mohammed Rachid ; Routy, Jean Pierre ; Leclerc, Denis ; Lapointe, Réjean. / Two distinct chimeric potexviruses share antigenic cross-presentation properties of MHC class I epitopes. In: Vaccine. 2010 ; Vol. 28, No. 34. pp. 5617-5626.
@article{7b6dc94236bf47f2b5ece367e3a41519,
title = "Two distinct chimeric potexviruses share antigenic cross-presentation properties of MHC class I epitopes",
abstract = "Chimeric VLPs made of papaya mosaic virus (PapMV) trigger a CTL response through antigenic presentation of epitopes on MHC class I. Here, a chimeric VLP composed of malva mosaic virus (MaMV) was shown to share similar properties. We demonstrated the capacity of both VLPs to enter human APCs. The chimeric constructions were cross-presented in CD40-activated B lymphocytes leading to in vitro expansion of antigen-specific T lymphocytes. We showed that high concentrations of chimeric MaMV induced cell death, suggesting that some modifications can trigger collateral effects in vitro. Results suggest that potexvirus VLPs are an attractive vaccine platform for inducing a CTL response.",
keywords = "Cross-presentation, Potexvirus, Virus-like particles",
author = "Hanafi, {La{\"i}la A{\"i}cha} and Maril{\`e}ne Bolduc and Gagn{\'e}, {Marie {\`E}ve Lalibert{\'e}} and Florent Dufour and Yves Langelier and Boulassel, {Mohammed Rachid} and Routy, {Jean Pierre} and Denis Leclerc and R{\'e}jean Lapointe",
year = "2010",
month = "8",
doi = "10.1016/j.vaccine.2010.06.024",
language = "English",
volume = "28",
pages = "5617--5626",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "34",

}

TY - JOUR

T1 - Two distinct chimeric potexviruses share antigenic cross-presentation properties of MHC class I epitopes

AU - Hanafi, Laïla Aïcha

AU - Bolduc, Marilène

AU - Gagné, Marie Ève Laliberté

AU - Dufour, Florent

AU - Langelier, Yves

AU - Boulassel, Mohammed Rachid

AU - Routy, Jean Pierre

AU - Leclerc, Denis

AU - Lapointe, Réjean

PY - 2010/8

Y1 - 2010/8

N2 - Chimeric VLPs made of papaya mosaic virus (PapMV) trigger a CTL response through antigenic presentation of epitopes on MHC class I. Here, a chimeric VLP composed of malva mosaic virus (MaMV) was shown to share similar properties. We demonstrated the capacity of both VLPs to enter human APCs. The chimeric constructions were cross-presented in CD40-activated B lymphocytes leading to in vitro expansion of antigen-specific T lymphocytes. We showed that high concentrations of chimeric MaMV induced cell death, suggesting that some modifications can trigger collateral effects in vitro. Results suggest that potexvirus VLPs are an attractive vaccine platform for inducing a CTL response.

AB - Chimeric VLPs made of papaya mosaic virus (PapMV) trigger a CTL response through antigenic presentation of epitopes on MHC class I. Here, a chimeric VLP composed of malva mosaic virus (MaMV) was shown to share similar properties. We demonstrated the capacity of both VLPs to enter human APCs. The chimeric constructions were cross-presented in CD40-activated B lymphocytes leading to in vitro expansion of antigen-specific T lymphocytes. We showed that high concentrations of chimeric MaMV induced cell death, suggesting that some modifications can trigger collateral effects in vitro. Results suggest that potexvirus VLPs are an attractive vaccine platform for inducing a CTL response.

KW - Cross-presentation

KW - Potexvirus

KW - Virus-like particles

UR - http://www.scopus.com/inward/record.url?scp=77955056229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955056229&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.06.024

DO - 10.1016/j.vaccine.2010.06.024

M3 - Article

VL - 28

SP - 5617

EP - 5626

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 34

ER -